Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 81

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 81
---
 in April 2024 were canceled.

46 (2)The amounts reported in this column represent (i) $13,200 in Company contributions made under our 401(k) plan and (ii) $2,835 in Company -paidlife insurance premiums during the fiscal year ended December 31, 2024. (3)In April 2024, Mr. Ehrlich received stock options to purchase 5,272 shares of common stock at $177.00 per share. Additionally, on October 1, 2024, Mr. Ehrlich received options to purchase 25,500 shares of common stock at $10.00 per share. On October 1, 2024, the options granted in April 2024 were canceled pursuant to an agreement between Mr. Ehrlich and the Company. (4)In April 2024, Mr. Atwood received stock options to purchase 13,180 shares of common stock at $177.00 per share and 139 shares of common stock at $528.00 per share. Additionally, on October 1, 2024, Mr. Atwood received options to purchase 5,080 shares of common stock at $10.00 per share. On October 1, 2024, the options granted in April 2024 were canceled pursuant to an agreement between Mr. Atwood and the Company. (5)In April 2024, Dr. Corey received stock options to purchase 8,567 shares of common stock at $177.00 per share. Upon his resignation, all unvested options were canceled. (6)In April 2024, Mr. Carter received stock options to purchase 3,954 shares of common stock at $177.00 per share. Upon his resignation, all unvested options were canceled upon his resignation. (7)On October 1, 2024, Mr. Kucharchuk received stock options to purchase 5,000 shares of common stock at $10.00 per share. (8)In April 2024, Dr. Pierce received stock options to purchase 659 shares of common stock at $36.00 per share. Additionally, on October 1, 2024, Dr. Pierce received stock options to purchase 2,000 shares of common stock at $10.00 per share. Narrative Disclosure to the 2024 Summary Compensation Table Compensation of our named executive officer for the fiscal year ended December 31, 2024 was determined